- Aicuris will present an overview of the pritelivir clinical development program, including a comprehensive Phase 2 data overview, in two oral presentations.
- Updated safety and pharmacokinetic data from the Phase 1 trial of AIC468, an antiviral therapy for BKV infections, will be shared in a poster presentation.
Wuppertal, Germany, September 16, 2025 – Aicuris announced today that it will present clinical updates from its antiviral pipeline in two oral presentations and a poster presentation at the 2025 ID Week Annual Meeting, scheduled for October 19–22, 2025, in Atlanta, Georgia.
The presentations will include pritelivir Phase 2 efficacy and safety results for treating refractory HSV infection, both with and without resistance, in immunocompromised patients, along with an overview of the pritelivir clinical development. Additionally, a poster presentation will feature updated safety and pharmacokinetic data from the first-in-human study of AIC468, a novel antisense oligonucleotide therapeutic that targets BK-Virus.
All abstracts will be available on the conference website starting October 19, 2025, at 12:01 AM ET.
In addition to the presentations, Aicuris’ medical team will be available at booth 422 throughout the conference to discuss pritelivir, the company’s lead candidate.
Oral Presentations
Title: Pritelivir: A novel non-nucleoside helicase primase inhibitor, for the treatment of herpes simplex virus (HSV) infections in Phase 3 clinical development
Presenting author: Alexander Birkmann, PhD, Vice President Virology and HSV Platform at Aicuris
Session: New antimicrobials in the pipeline
Date/ Time: October 20, 2025 / 8:45 AM – 9:00 AM ET
Location: B302 – B304
Title: Efficacy and safety results from the Phase 2 clinical trial of pritelivir versus foscarnet for the treatment of acyclovir-refractory and/or resistant mucocutaneous HSV infections in immunocompromised subjects
Presenting author: Camille N. Kotton, MD, FIDSA, FAST, Clinical Director, Transplant and Immunocompromised Host Infectious Diseases, Massachusetts General Hospital
Session: New anti-infective agents
Date/ Time: October 20, 2025 / 3:51 PM – 4:03 PM ET
Location: B213 – B214
Poster Presentation
Title: Interim results of the first-in-human Phase 1 trial of AIC468: A novel antisense oligonucleotide that targets BK-Virus transcripts (P113)
Presenting author: Susanne Bonsmann, Head of Pharmacokinetics at Aicuris
Session: Clinical Trials
Date/ Time: October 20, 2025 / 12:15 PM – 1:30 PM US ET
Location: Poster Hall B4-B5
About Pritelivir
Pritelivir, a helicase-primase inhibitor created by Aicuris, is designed to target HSV-1 and HSV-2, viruses that cause genital, oral, or disseminated infections, which are becoming increasingly severe and resistant in immunocompromised individuals. Unlike conventional antivirals, pritelivir prevents viral DNA synthesis by targeting the helicase-primase complex, a different mechanism than that of existing nucleoside analogues. Because pritelivir does not need to be activated by viral proteins, it may be less vulnerable to resistance.1 Prior studies in both immunocompetent and immunocompromised individuals have indicated a good safety profile and improved clinical efficacy compared to standard treatments such as valacyclovir and foscarnet, including resistant or refractory strains. Enrollment for the pivotal Phase 3 trial PRIOH-1 completed in August. The trial results will be used to support marketing authorization applications in 2026.
About AIC468
AIC468, an antisense oligonucleotide therapy, aims to address BK virus reactivation in kidney transplant recipients, a condition that can pose significant health risks. This therapeutic candidate works by blocking viral replication within infected cells through the inhibition of splicing of the pre-mRNA, which encodes the virus’ large T-antigen. This innovative strategy has shown strong antiviral activity, along with a favorable pharmacokinetic and safety profile, in preclinical studies, and is currently being evaluated in a Phase 1 clinical trial.
About Aicuris
Aicuris is focused on providing targeted therapies for the growing population of immunocompromised individuals who require effective treatments for infections. PREVYMIS®, the company’s flagship product, is marketed by its partner MSD to prevent CMV in specific groups of transplant recipients. Pritelivir, a Phase 3 candidate, is intended to treat refractory HSV infections in a wide range of patients with weakened immune systems. For immunocompromised individuals, infections that would otherwise be manageable can be life-threatening. Aicuris is dedicated to offering therapeutic solutions for these patients, both now and in the future, through its expertise and expanding pipeline.
Contact:
Aicuris Anti-infective Cures AG
info@aicuris.com
Trophic Communications
Dr. Stephanie May and Dr. Charlotte Spitz
Phone: +49 171 3512733
Email:
1 Sallée, L. and Boutolleau, D. (2024), Management of Refractory/Resistant Herpes Simplex Virus Infections in Haematopoietic Stem Cell Transplantation Recipients: A Literature Review. Rev Med Virol, 34: e2574.
“`